Regeneron Announces Presentation at the Barclays Capital Global 2010 Healthcare Conference
TARRYTOWN, N.Y., March 18, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Barclays Capital Global 2010 Healthcare Conference on Tuesday, March 23, 2010. The presentation is scheduled for 10:15 a.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through April 22, 2010.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.
Contact Information:
Peter Dworkin Laura Lindsay
Investor Relations Media Relations
914.345.7640 914.345.7800
peter.dworkin@regeneron.com laura.lindsay@regeneron.com
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved